Loroblis, 16 tablets, Innergy

Streptococcus salivarius K12 is a bacterial strain that colonizes the oral cavity and nasopharynx of healthy individuals and is part of the normal bacterial flora.

Restores eubiosis at the level of the oral cavity, oropharynx and nasopharynx.

Streptococcus salivarius K12 produces 2 bacteriocins that have the potential to inhibit the development of pathogenic bacterial strains (for example: Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, responsible for bacterial pharyngitis and tonsillitis, acute otitis media and halitosis).

Streptococcus salivarius K12 has antiviral, anti-inflammatory and antifungal activity, supported in over 20 studies on human subjects.

Benefits:

Clinical studies have shown that Loroblis® contributes to the maintenance and development of a protective microbial flora in the oral cavity and pharynx, with the potential to

• Improvement of manifestations associated with upper respiratory tract infections - 1 tablet/day, 90 days (especially in the cold season)
• Improvement of manifestations associated with oral inflammatory diseases - 1 tablet/day, 30 days.

Composition:

1 LOROBLIS® orodispersible tablet contains at least 1x10⁹ CFU Streptococcus salivarius K12 (BLIS® K12) + vitamin D3/ cholecalciferol (200 IU).

How to use:

• 1 tablet/day, evening after oral hygiene, minimum 3 months (especially during the cold season and before the start of the school year)
• For children over 3 years old and adults.

Precautions:

• Administration is done in the evening, after oral hygiene, without consuming liquids or food
• It is unnecessary to administer concomitantly with antibiotics
• Contraindicated in immunocompromised patients, with chemotherapy, radiotherapy, severe leukopenia.

Presentation: 16 orodispersible tablets